Search This Blog

Monday, June 29, 2026

Palisade FDA IND clearance for PALI-2108 to initiate Phase 2 ASCENTRA-UC ulcerative colitis trial

 


  • ASCENTRA-UC is a global Phase 2 study in moderately to severely active ulcerative colitis patients.
  • First patient enrollment in the ASCENTRA-UC trial is expected in the second half of 2026.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)